The objective was to evaluate the association between antiretroviral therapy and AIDS mortality in New York City (NYC). Design was a population-based case-control study. We randomly selected 150 case patients and 150 control patients whose AIDS diagnosis was made during 1994 to 1996 (male : female, 2 : 1) from among 19,238 persons reported to the NYC Health Department HIV/AIDS Reporting System (HARS). Case patients had died of AIDS-related causes in 1996. Control patients, category matched with case patients on gender, were not known to have died by the end of 1996. Analysis was performed on 279 patients (142 cases and 137 controls). Cases and controls were similar in age, gender, race, HIV transmission category, and health insurance coverage. The median baseline CD4 count was 30 cells/~L for those who died and 103 cells/~L for survivors (p < .0.001). The prescription of HAART (antiretroviral combination that includes at least one protease inhibitor) in 1996 was strongly associated with survival in univariate analysis (OR = 5.1, 95%CI = 2.5-10.2). This association remained in a logistic regression analysis after adjusting for sex, age, race, health insurance status, HIV transmission categories, year of AIDS diagnosis, baseline CD4 count, and other antiretroviral therapy (AOR = 8.6, 95%CI = 3.5-20.7). Prescription of combination therapy other than HAART in 1996 and baseline CD4 count were also associated with survival, but less strongly so. The survival benefit of HAART extends beyond the confines of a few highly selected patients into the "real world," reducing AIDS deaths at the population level. This population-based study sup-
ports the likelihood that the introduction of HAAT in 1996 played a primary role in the decline in NYC AIDS mortality.
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INTRODUCTION
Since the beginning of the acquired immunodeficiency syndrome (AIDS) epidemic, over 700,000 cases have been reported nationally. New York City suffered a heavy toll by having the largest number of cases of any single American city, with over 110,000 cases reported to date. 1 The transmission risk categories in New York City are diverse, including men having sex with men (MSM), injecting drug users (IDUs), and heterosexuals. Of all reported AIDS cases in the city, females account for 22%, IDUs account for 42%, and more than 75% are people of color. 2
Beginning in 1996, the number of AIDS deaths declined in New York City, 3 from an average of 20 per day in 1995 to 6 per day in 1998. Because this reduction in deaths coincided with the introduction of protease inhibitors, it has been hypothesized that highly active antiretroviral therapy (HAART) combinations that include at least one protease inhibitor might have played a role in this decline. 4~ Clinical trials have shown that HAART reduces mortality in highly selected and rigorously monitored patients. 7~ To assess the public health impact at the population level, we evaluated the association between antiretroviral therapy and mortality among persons with AIDS in New York City in 1996, the year when HAART was first available widely.
METHODS
STUDY DESIGN AND POPULATION
We conducted a case-control study among all persons with AIDS diagnosed in New York City between 1994 and 1996, aged 25-59 years, who were reported to the New York City Health Department HW/AIDS Reporting System (HARS). The sample size calculation was based on a confidence interval (CI) of 95%, power of 80%, and combination antiretroviral use by 79% of control patients to detect an odds ratio (OR) of at least 2.5.
DATA COLLECTION
Trained public health staff familiar with AIDS surveillance data abstraction collected data for 1995 and 1996. Several data sources were used: HARS, records from facilities concerning AIDS diagnosis/death, death certificates, and records from additional facilities identified through chart reviews or through a CD4 reporting mechanism by which laboratories report counts less than 200 cells/pL to HARS. Viral load testing was not the standard of practice during the study period; therefore, results were not available for the majority of patients. Standardized data collection forms were used. Patient interviews were not performed.
STATISTICAL ANALYSIS
We categorized antiretroviral therapy based on the most advanced regimen used as none, monotherapy, HAART (defined as an antiretroviral combination that included at least one protease inhibitor), and combination therapy other than HAART. Subjects were excluded from the analysis of medication use if no such information was available. The baseline CD4 count closest to the time of AIDS diagnosis was used for all analyses.
A stepwise logistic regression model was used to assess the association between antiretroviral therapy and AIDS survival while controlling for continuous variables (age, baseline CD4 count) and categorical variables (gender, race, health insurance status, human immunodeficiency virus [HIV] transmission category, and year of AIDS diagnosis). SAS 6.12 (SAS Institute, Cary, NC) and Epi Info 6.04 (CDC, Atlanta, GA) were used for data analyses. All statistical tests were two sided, and a P value less than .05 was considered to indicate statistical significance.
RESULTS
Of the 300 patients, 21 were excluded from the analysis: Two control patients could not be identified adequately because of conflicting demographic data, 3 control patients had received their medical care outside New York City, and 8 patients from each group actually were diagnosed with AIDS before 1994. These excluded patients did not differ significantly from the rest of the sample in age, gender, HIV transmission category, health insurance status, and baseline CD4 count. There were slightly fewer minorities in the excluded group (62% vs. 82%, P = .04).
PATIENT CHARACTERISTICS
The patients in our sample were similar to the AIDS population in New York City from which they were selected after taking into account differences in race and transmission categories inherent in the intentional oversampling of women (Table I) . Cases were similar to controls in age, gender, race, HIV transmission category, and health insurance coverage.
PREDICTORS OF AIDS SURVlVA"
The median baseline CD4 count was 30 cells/ilL for those who died and 103 cells/IlL for the survivors (P < .001). Those who died were more likely to have been diagnosed with AIDS before 1996 (P < .05) (Table II) .
In univariate analysis, antiretroviral therapy status was associated with survival (Table III) . Those who survived were more likely to have been prescribed antiretrovirals compared to those who died (OR = 3.5, 95% CI 1.8-6.7). In particular, they were more likely to have been prescribed HAART (OR = 5.1, 95% CI 2.5-10.2). The above association persisted after stratification by year of AIDS diagnosis or by baseline CD4 count; HAART was associated with increased survival even in those with very low CD4 count (<50 cells/IlL). To allow cases a greater opportunity to initiate HAART in 1996 when it first became available, we compared those cases who survived through at least the first 6 months in 1996 to the controls. HAART remained associated with increased survival (OR = 2.3, 95% CI 1.1-5.1) (Table II) .
In multivariate analysis controlling for gender, age, race, health insurance status, HIV transmission category, years of AIDS diagnosis, baseline CD4 count, and antiretroviral therapy, the prescription of HAART in 1996 had the strongest association with survival (adjusted OR = 8.6, 95% CI 3.5-20.7) (Table IV) . Prescription of combination therapy other than HAART in 1996 and baseline CD4 count were associated less strongly with survival.
Despite extensive chart reviews at each treatment facility, antiretroviral data were missing for 51 patients. To ensure that the missing data would not have changed the conclusions of the study, we repeated the univariate analyses using two assumptions. First, we assumed that none of those with missing information were prescribed antiretrovirals. The analysis was then repeated assuming that all these 51 patients were prescribed HAART. In both scenarios, the strong association between survival and HAART remained (P < .001) ( Table V) .
DISCUSSION
Clinical trials have shown that HAART can reduce mortality in highly selected and closely monitored HIV-infected patients in ideal research settings. 4~ Subsequently, observational studies have suggested survival benefits in patients attend- Some limitations of our study need to be discussed. Our study does not take into account frequent antiretroviral regimen changes, regimen duration, or variations in drug dosage. To address the potential survivor treatment selection bias, we compared those cases who died in the last half of 1996 to the controls.
HAART remained associated with increased survival. In addition, as HAART coverage increased in New York City after the study period, AIDS mortality continued to decline. 22
In conclusion, the decline in AIDS deaths in New York City in 1996 was rapid and coincided with the introduction of HAART. Our study findings support the hypothesis that the introduction of HAART in 1996 played a primary role in the decline in AIDS mortality in New York City.
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